Compare · AUPH vs AZN
AUPH vs AZN
Side-by-side comparison of Aurinia Pharmaceuticals Inc (AUPH) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AUPH and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 116.1x AUPH ($2.23B).
- Over the past year, AUPH is up 39.6% and AZN is up 97.3% - AZN leads by 57.7 points.
- AZN has hit the wire 14 times in the past 4 weeks while AUPH has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 15 for AUPH).
- Company
- Aurinia Pharmaceuticals Inc
- AstraZeneca PLC
- Price
- $16.52-1.17%
- $165.42-0.74%
- Market cap
- $2.23B
- $258.47B
- 1M return
- -2.51%
- -0.43%
- 1Y return
- +39.57%
- +97.28%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 0
- 14
- Recent ratings
- 15
- 25
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AUPH
- Chief Legal Officer Robertson Stephen P. sold $190,427 worth of shares (11,939 units at $15.95), decreasing direct ownership by 2% to 588,848 units (SEC Form 4) to cover withholding tax
- Chief Legal Officer Robertson Stephen P. sold $355,946 worth of shares (20,975 units at $16.97), decreasing direct ownership by 3% to 600,787 units (SEC Form 4) to cover withholding tax
- Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Aurinia Settles Patent Litigation with Teva
- SEC Form 10-Q filed by Aurinia Pharmaceuticals Inc
- Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
- Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
- SEC Form 4 filed by Director Johnson Craig A
- SEC Form 4 filed by Director Goetz Kathleen
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC